Physician profile
Nancy Chen
NPI 1144846213
$1,397.53
in general payments reported to CMS, 2019-2025
16 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $240 · 2023: $219 · 2024: $804 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.71 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.58 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $335.84 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $154.74 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $63.68 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $41.86 | 2023-2024 | Nexletol, Contrave |
| Vanda Pharmaceuticals INC. | $39.09 | 2024 | Hetlioz, Fanapt |
| Organon LLC | $34.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.52 | 2024-2025 | Xifaxan, Trulance |
| Vbi Vaccine (Delaware) INC. | $26.44 | 2023 | Prehevbrio |
| Otsuka America Pharmaceutical, INC. | $23.34 | 2024 | Rexulti |
| Medtronic, INC. | $21.12 | 2022 | |
| Exact Sciences Corporation | $20.83 | 2025 | The Cologuard Plus Collection Kit |
| Tris Pharma INC | $20.24 | 2024 | Dyanavel Xr |
| Dexcom, INC. | $16.95 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.47 | 2024 | Capvaxive, Gardasil 9, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.